Science AI Journal
Medicine · Research topic

Open research questions in Bladder and Urothelial Cancer Treatments

166 unresolved questions extracted from the limitations and future-work sections of 547 Bladder and Urothelial Cancer Treatments papers in our library. Each links back to the study that raised it.

What the literature leaves open

  • The paper identifies the lack of independent external validation of biomarkers as a research gap. The authors highlight the need for nuanced understanding of validation and transparent reporting. The paper argues that the current state of biomarker validation is limited by the misuse of the term 'validated'.

    Comment on “A molecular landscape tracking the progression of non-muscle invasive bladder cancer” · 2026 · DOI

  • The paper identifies challenges in the management of NMIBC, including the high recurrence rate and prolonged disease course. The heterogeneity of TCM syndrome characteristics and pharmacological evidence poses a challenge for standardized reporting and intervention characterization. The limited direct evidence for reducing NMIBC recurrence or progression is a challenge for the development of effective treatments.

    Traditional Chinese medicine in non-muscle-invasive bladder cancer: a scoping review of syndrome characteristics and critical synthesis of pharmacological and mechanistic evidence · 2026 · DOI

  • Much of the mechanistic evidence derives from broader bladder cancer experimental models or predictive analyses, - Direct evidence for reducing NMIBC recurrence or progression remains limited, - The scoping review was designed to map literature-reported syndrome terminology and occurrence patterns rather than to estimate treatment effects or patient-level prevalence

    Traditional Chinese medicine in non-muscle-invasive bladder cancer: a scoping review of syndrome characteristics and critical synthesis of pharmacological and mechanistic evidence · 2026 · DOI

  • Lack of standardized methodologies, - Risks of potential contamination in urine samples, - Extremely invasive nature of bladder tissue biopsy, - Differences between fresh-frozen and formalin-fixed paraffin-embedded tissue

    The Urinary Microbiome in Health and Disease: Relevance for Bladder Cancer · 2024 · DOI

  • Investigation into the urinary microbiome of BC patients, - Examination of bladder tissue to reduce potential contamination risks, - Study of the effect of age on the urinary microbiome, - Exploration of the potential profiling of urinary microbiota as a biomarker

    The Urinary Microbiome in Health and Disease: Relevance for Bladder Cancer · 2024 · DOI

  • a researcher deciding which of these biomarkers merits a prospective, multicenter validation study

    Comment on “A molecular landscape tracking the progression of non-muscle invasive bladder cancer” · 2026 · DOI

  • Immune checkpoint inhibitors (ICI) have transformed cancer therapy, yet their efficacy remains limited to a subset of patients, underscoring the need for robust predictive biomarkers and deeper mechanistic insights into treatment resistance.

    CCL5 hiCD4+ T Cells Regulate Macrophage Polarization and Promote Immunotherapy Response in Bladder Cancer · 2026 · DOI

  • Background: Epidemiological studies have shown inconsistent results in associations between soy consumption and bladder cancer (BC).

    Soy Consumption and the Risk of Developing Bladder Cancer: A Pooled Analysis of Cohort Studies from the International Pooled Bladder Cancer Epidemiology and Nutritional Determinants (BLEND) Study · 2026 · DOI

  • Previous studies have highlighted the roles of cancer-associated fibroblasts (CAFs) and exhausted T (Tex) cells in MIBC, but their interactive mechanisms remain poorly understood.

    Single-cell RNA sequencing reveals a fibroblast gene signature that promotes T-cell infiltration in muscle-invasive bladder cancer · 2025 · DOI

  • Future research should focus on large-scale clinical validation and standardization of biomarkers to facilitate their use in routine clinical practice.

    Novel Urinary Biomarkers for the Detection of Bladder Cancer · 2025 · DOI

  • Background: The role of molecular imaging in urothelial cancer is less defined than other cancers, and its utility remains controversial due to limitations such as high urinary tracer excretion, complicating primary tumour assessment in the bladder and upper urinary tract.

    Nuclear Medicine and Molecular Imaging in Urothelial Cancer: Current Status and Future Directions · 2025 · DOI

  • These findings underscore the importance of personalized treatment approaches, and future research is warranted to refine enfortumab vedotin-based therapies for mUC management.

    Enfortumab Vedotin With or Without Pembrolizumab in Metastatic Urothelial Carcinoma · 2025 · DOI

  • The molecular and cellular mechanisms contributing to BLCA ITH generation remain elusive.

    Integrative Single Cell Atlas Revealed Intratumoral Heterogeneity Generation from an Adaptive Epigenetic Cell State in Human Bladder Urothelial Carcinoma · 2024 · DOI

  • Abstract Circulating tumor DNA (ctDNA) is emerging as a potential biomarker in early-stage urothelial cancer, but its utility in metastatic disease remains unknown.

    Pembrolizumab for advanced urothelial carcinoma: exploratory ctDNA biomarker analyses of the KEYNOTE-361 phase 3 trial · 2024 · DOI

  • Treatment of BCG-unresponsive tumors is scarce and usually leads to Radical Cystectomy.

    Revolutionizing Treatment: Breakthrough Approaches for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer · 2024 · DOI

  • However, data evaluating its variability and susceptibility to Bacillus Calmette–Guérin (BCG) therapy in HR NMIBC patients is scarce.

    PD-L1 Expression in High-Risk Non-Muscle-Invasive Bladder Cancer Is Influenced by Intravesical Bacillus Calmette–Guérin (BCG) Therapy · 2024 · DOI

  • However, scarce evidence exists regarding cancer-specific mortality (CSM) differences between trimodal therapy and other non-extirpative multimodal treatment options such as radiotherapy alone after transurethral resection (TURBT + RT) or chemotherapy alone after transurethral resection (TURBT + CT).

    Non-Surgical Bladder-Sparing Multimodal Management in Organ-Confined Urothelial Carcinoma of the Urinary Bladder: A Population-Based Analysis · 2024 · DOI

  • The available evidence regarding possible differences in clinical efficacy between various BCG strains in CIS is lacking.

    Carcinoma In Situ (CIS): Is There a Difference in Efficacy between Various BCG Strains? A Comprehensive Review of the Literature · 2024 · DOI

  • BACKGROUND/OBJECTIVES: The efficacy of lung metastasectomy in patients with urothelial carcinoma remains inconclusive, as there is only limited evidence from small studies.

    Survival after Lung Metastasectomy from Urothelial Carcinoma: A Multi-Institutional Database Study · 2024 · DOI

  • However, outcomes remain poor, and little is known about current treatment approaches and attrition rates for patients with aUC.

    Treatment Patterns and Attrition With Lines of Therapy for Advanced Urothelial Carcinoma in the US · 2024 · DOI

  • Guidelines recommend 24 hours or less of PAP for cystectomy with urinary diversion; however, evidence specifying optimal PAP duration for this surgery is lacking, and prolonged administration of PAP is common practice.

    Perioperative Antibiotic Prophylaxis Duration in Patients Undergoing Cystectomy With Urinary Diversion · 2024 · DOI

  • Identifiability constraints in the full model with independent potency parameters. The need to account for between-subject and between-assay variation. The challenge of developing a robust in vitro platform for assessing chemoradiation efficacy and potency.

    Innovative In Vitro-In Silico Platform for Dose–Response Modeling in Canine Bladder Cancer: A 3D Organoid- and Mathematics-Based Approach · 2026 · DOI

  • Future development of personalized and optimized chemoradiation strategies in canine and human bladder cancer. Evaluation of the platform's potential for assessing chemoradiation efficacy and potency in other cancer types.

    Innovative In Vitro-In Silico Platform for Dose–Response Modeling in Canine Bladder Cancer: A 3D Organoid- and Mathematics-Based Approach · 2026 · DOI

  • investigation of molecular features or microenvironmental influences that could explain the discrepancies in outcomes, - further validation of the results in larger cohorts, - exploration of the temporal and spatial dimensions of urothelial carcinogenesis

    Differentiating Upper Tract Urothelial Carcinoma with Synchronous or Metachronous Bladder Cancer · 2026 · DOI

  • The study had a limited follow-up period of 25.6 months. The trial was amended multiple times, which may have affected the results. Adverse events were common in both groups.

    Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer · 2026 · DOI

Most-cited papers in Bladder and Urothelial Cancer Treatments

Most recent work

Find a gap in your own Bladder and Urothelial Cancer Treatments sub-topic

This page shows what the Bladder and Urothelial Cancer Treatments literature already flags as unresolved. To narrow it to your specific question, run the guided finder — it searches the gap library on demand and checks candidates against 250M+ OpenAlex works.

Open the Research Gap Finder →

Related topics in Medicine

Artificial Intelligence in Healthcare and Education
2,044 open questions
Substance Abuse Treatment and Outcomes
1,964 open questions
Smoking Behavior and Cessation
990 open questions
Dementia and Cognitive Impairment Research
974 open questions
Innovations in Medical Education
960 open questions
Physical Activity and Health
923 open questions
Attention Deficit Hyperactivity Disorder
839 open questions
Schizophrenia research and treatment
709 open questions
166 open questions have been extracted from the limitations and future-work passages of 547 Bladder and Urothelial Cancer Treatments papers in our library. Each one below links back to the study that raised it, so you can read the original claim in context.

Tools for your next paper

Gaps & Literature SearchFind open questions in any field — 120,000+ open gaps mined from our own library.Pre-CheckIs your paper ready? A Tier 1–5 acceptance probability in seconds.Journal FinderA ranked shortlist of target journals from a 17,500-venue index.Duplicate Publication CheckerCheck prior-publication & salami-slicing risk across 8 sources.Citation GeneratorFreeA DOI or title → APA, MLA, Vancouver, Chicago, BibTeX, RIS. No signup.Graphical Abstract MakerFreeTurn your findings into a colorblind-safe graphical abstract.

Compare the category — Honest roundups of the AI research tools, ours listed alongside the alternatives.

Command palette

Jump anywhere, run any action.